Abstract
Behçet’s disease is a chronic inflammatory disease characterized by recurrent oral aphthae and systemic manifestations. Gastrointestinal involvement is rare. We report a case of ileocolitis secondary to Behçet’s successfully treated with tumor necrosis factor–alpha antibody (infliximab) therapy. To our knowledge this is the second reported case of Behçet’s ileocolitis successfully treated with anti–tumor necrosis factor therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
T Sakane M Takeno N Suzuki G Inaba (1999) ArticleTitleCurrent concepts Behçet’s disease N Engl J Med 341 1284–1291
InstitutionalAuthorNameInternational Study Group for Behçet’s Disease (1990) ArticleTitleInternational Study Group for Behçet’s Disease Lancet 335 1078–1080
T Lehner (1997) ArticleTitleThe role of heat shock protein, microbial and autoimmune agents in the etiology of Behçet’s disease Int Rev Immunol 14 21–32
B Turan H Gallati H Erdi et al. (1997) ArticleTitleSystemic levels of the T cell regulatory cytokines IL-10 and IL-1 in Behçet’s disease; soluble TNFR-75 as a biological marker of disease activity J Rheumatol 24 128–132
Y Bayraktar E Ozaslan DH Van Thiel (2000) ArticleTitleGastrointestinal manifestations of Behçet’s Disease. J Clin Gastroenterol. 30 144–154
LA Orloff MJ Orloff (1999) ArticleTitleBudd-Chiari syndrome caused by Behçet’s J Am Coll Surg 188 396–407
S Yurdakul N Tuzuner I Yurdakul V Hamuryudan H Yazici (1996) ArticleTitleGastrointestinal involvement in Behçet’s syn-drome Ann Rheum Dis 55 208–210
J Masugi T Matsui T Fujimoro S Maeda (1994) ArticleTitleA case of Behçet’s disease with multiple longitudinal ulcers all over the colon Am J Gastroenterol 89 778–780
IJ Choi JS Kim SD Cha et al. (2000) ArticleTitleLong term clinical course and prognostic factors in intestinal Behçet’s disease Dis Colon Rectum 43 692–700
LL Ketch CA Buerk RD Liechty (1980) ArticleTitleSurgical implications of Behçet’s disease Arch Surg 115 759–760
S Yamazaki T Koyano (1999) ArticleTitleA case of pediatric Behçet’s with intestinal involvement J Dermatol 26 160–163
SR Targan SR Hanauer SJ van Deventer et al. (1997) ArticleTitleA short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease N Engl J Med 337 1029–1035
DH Present P Rutgeerts S Targan et al. (1999) ArticleTitleInfliximab for the treatment of fistulas in patients with Crohn’s disease N Engl J Med 340 1398–1405
PV Hassard SW Binder V Nelson EA Vasiliauskas (2001) ArticleTitleAnti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease Gastroenterology 120 995–999
Author information
Authors and Affiliations
About this article
Cite this article
Kram, M.T., May, L.D., Goodman, S. et al. Behçet’s Ileocolitis: Successful Treatment With Tumor Necrosis Factor–Alpha Antibody (Infliximab) Therapy. Dis Colon Rectum 46, 118–121 (2003). https://doi.org/10.1007/s10350-004-6506-4
Issue Date:
DOI: https://doi.org/10.1007/s10350-004-6506-4